Home testing kits, coordinated outreach improve CRC screening rates

New colorectal cancer screening strategies must advance the standard of care

Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical for reducing incidence and preventing deaths from this disease.

Johns Hopkins, Howard University reform collaboration to advance health equity

A collaborative effort to eliminate cancer health disparities among African Americans and other underserved populations in the Washington, DC, area is being reignited at the Johns Hopkins Kimmel Cancer Center and the Howard University Cancer Center.

January 10, 2025

Vol.51 No.01

In Brief

UH and John A. Burns School of Medicine form initiative focused on health outcome disparities in Hawai‘i and the Pacific

The University of Hawai‘i Cancer Center and the John A. Burns School of Medicine are forming Ka ʻUmeke Lama, an initiative to transform cancer care in Hawaiʻi and the Pacific.

January 10, 2025

Vol.51 No.01

In Brief

ASC CAN: Congress missed a critical opportunity to prioritize cancer prevention and access to care

In December, Congress failed to advance a bipartisan year-end health care package that would have made a big difference in the fight against cancer, according to the American Cancer Society Cancer Action Network.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA granted accelerated approval to encorafenib (Braftovi) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

January 10, 2025

Vol.51 No.01

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC

The European Commission has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.

January 10, 2025

Vol.51 No.01

Home testing kits, coordinated outreach improve CRC screening rates

YOU MAY BE INTERESTED IN

New colorectal cancer screening strategies must advance the standard of care

Johns Hopkins, Howard University reform collaboration to advance health equity

UH and John A. Burns School of Medicine form initiative focused on health outcome disparities in Hawai‘i and the Pacific

ASC CAN: Congress missed a critical opportunity to prioritize cancer prevention and access to care

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC

Renew today!

Subscriber content

Never miss an issue!

Login